The first part of the influential CPHI Annual Report predicts sizeable progress ahead for AI’s use in pharma, as despite the wider excitement around ChatGPT and other generative AI’s having cooled in recent months, pharma’s real-world applications continue to expand. The implications go far beyond its current use and most startling of all – notwithstanding the so far limited successes – it is expected that within 10-years over 50% of approved drugs will involve AI in their development and/or manufacturing.

The CPHI Report’s AI findings, which are released ahead of CPHI Barcelona, the world’s largest pharma event, held at Fira Barcelona (October 24-26th, 2023), point to the technology having a transformational impact on all parts of drug discovery and development within the next 24-months.

Speaking on the immediate impact to pharma, CPHI Report expert Bikash Chatterjee – and Chief Science Officer, Pharmatech Associates, a USP Company – added: The tools we have today to evaluate genetic material and protein structures are tremendous. As we gather data, the models we use for evaluation within AI will improve and our criteria and insight will become more refined, allowing us to design and direct evaluation models more efficiently. I would agree that we are very near to seeing AI discovered molecules getting approved today—definitely within the next two to five years. In the next decade it is likely most drug therapies will be identified by some element of AI.

The CPHI Report features the insights from 250 global pharma companies and is widely seen as a key barometer of the industry's future growth prospects. For the first time in the report’s history pharmaceutical ‘AI companies’ (26%) have overtaken ‘late stage’ (20%) and ‘early stage’ (19%) biotechs as the industry’s most appealing investment option for VCs.

Significantly, the rate of change appears to be accelerating, with 62% forecasting that the first fully AI drug discovered and developed therapy will be approved by the FDA within the next 5 years – with 20% believing this can be achieved in under 2-years. Looking further ahead, by 2030, over half (52%) of new drugs approved will be discovered or developed using AI.

In fact, highlighting AI’s evolution and its expected far wider medium-term impact across pharma, it was predicted by executives to be central to all four of the top ranked technologies to breakthrough into ‘routine use’ by pharma in 2026’. Costs are also predicted to be lower as clinical trial designs are improved alongside in silico modelling and manufacturing efficiencies, with even clinical trial patient recruitment benefiting from the technology’s ability to analyse massive datasets. Unsurprisingly, AI’s role in target discovery (60+%) and manufacturing optimisation (52%) remained the most chosen application looking three years ahead, but nearly 43% also envisage it will even help to build base regulatory submissions.

Chatterjee added: Adoption will be fastest – initially – for drug discovery as there are no GMP or compliance requirements and, given the poor success rate of drugs that make it to market, going from 9 out of 10 drugs failing to 8 out of 10 drugs failing would be doubling of current success rates. Its potential impact cannot be overstated.

The CPHI Annual Report 2023 will be available in full on October 23rd, featuring detailed insights from over 10 experts and the CPHI Annual Survey and Country rankings. It will be available at:https://www.cphionline.com/reports/?utm_source=pressrelease&utm_medium=referrer utm_campaign=HLN00CPO-CL-AnnualReport&utm_content=AI

“There is no doubt that AI will change ways of working in pharma – we have entire conference tracks on next-gen biomanufacturing and manufacturing 4.0 at CPHI Barcelona 2023, and over the years have seen the conversation shift from potential applications to tangible impact. We are now seeing AI used not only to further improve target discovery – but also to deliver step-change improvements in manufacturing, process efficiencies and clinical trials. In as little as two years our experts predict many companies will have been left behind, with CDMOs having a great incentive to pivot quickly to keep pace with the expectations of their big pharma customers,” added Tara Dougal,

Content Director – Pharma at Informa Markets Informa Markets.

Register to attend CPHI Barcelona today and learn more about next generation manufacturing and access the global pharma supply chain. Connect with thousands of industry leaders and expand your network with endless opportunities to learn, innovate, and collaborate online and in-person.

Notes to editors

Description automatically generated with medium confidence

About CPHI Annual Report

The 2023 CPHI Annual Report’s survey of over 300 industry executives from over 35 countries provides an annual insight into the growth and development of the pharma industry globally.  The survey evaluates likely trends for 2024 and assesses the reputations of major pharma markets across more than 10 separate metrics. The findings of the survey will be released in press releases marked “CPHI Annual Survey”.  The second component of the CPHI Annual Report features the analysis of ten global experts, each exploring different aspects of the industry today and looks ahead to predict the major trends of tomorrow. The key insights of these mini reports will be shared in press releases marked “CPHI Annual Report”

About CPHI

CPHI is the leading global community for pharmaceutical professionals, hosting a portfolio of digital and in-person connection opportunities across the whole pharma supply chain on a scale like no other

At the heart of Pharma

CPHI Barcelona (24-26 October 2023 at Fira Barcelona, Barcelona), CPHI & PMEC India (28-30 November 2023 at the India Expo Mart, Greater Noida, Delhi NCR – Delhi, India); Pharmapack Europe (24-25 Jan, 2024 at Paris Expo, Porte de Versailles - Hall 7.2, Paris). CPHI Japan (17-19 April, 2024 at the Big Sight Exhibition Centre – Tokyo, Japan); CPHI North America (7-9 May, 2024 at Pennsylvania Convention Center, United States); CPHI China (19-21 June 2024 at SNIEC – Shanghai, China); CPHI South East Asia (12-14 Jul 2023 at QSNCC, Bangkok, Thailand); With support from year-round pharma news, products and services at CPHI Online.

About Informa Markets

Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world’s leading exhibitions organizer, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year.

For more information, please visit www.informamarkets.com.
For media enquiries, please contact:
Alex Heeley or Nidhi Narain
De Facto Communications
T: +44 (0) 203 735 8165 /  +44 (0) 7769015043
E: n.narain@defacto.co.uk  / a.heeley@defacto.co.uk

Report Abuse